The company of Insightful Science and Dotmatics has been named the official name and brand for the two entities. Many of the Dotmatics'' leading experts are offering a combination of both the enterprise scientific platform and SnapGene, Geneious, and GraphPad Prism as well as end-to-end solutions for biology, chemistry, and formulations research and development.
Scientific knowledge and growth in pharmaceutical drug discovery and chemicals & materials innovation are under way. It''s no longer the first time that science is fully understood.
COVID emphasized the necessity for rapid scientific research and collaboration to lead to faster, more successful breakthroughs. However, the complexity of getting and using scientific data in meaningful ways has resulted in poor results among researchers and scientists. The industry has had a lack of an integrated R&D platform that includes the depth, breadth, and connections to other applications to deal with complex data challenges in labs.
To combat workflow and data complicate, Dotmatics develops an integrated R&D platform with applications.
Dotmatics has a platform that connects and organizes information that is distributed across a wide range of industries, combining it with market-leading science applications for quick access, collaboration, and informed decision-making.
Companies that possess the best annotated data to guide their AI analytics and decision making will be the best in charge of this new paradigm, according to Thomas Swalla, CEO of Dotmatics. We are going to market under the consolidated brand Dotmatics, which represents the company''s enormous potential to provide this capability to our customers. We can then transform scientific research and research with a data-based platform that then connects industry-leading applications to better improve harmonize science and data.
Debiopharm, a pharmaceutical companies that wants to harmonize their science and data, has developed innovative therapies that target high unmet medical needs in oncology and infectious diseases. Together they identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to ensure patient access globally.
"Dotmatics has really disrupted the way Debiopharm works for the better," said Rene van den Bersselaar, head of IT and CIO of Debiopharm. Dotmatics has sparked a shift in the company''s culture, and were now making better, more data-driven decisions, helping us be more competitive and enabling us to develop new therapies for patients faster.
Dotmatics, a company that provides information to industry leaders in the world''s leading biotech, biopharma, chemicals & materials organizations, and academic institutions, will help accelerate innovation and make the world a healthier, cleaner, and safer place to live.
According to Dotmatics'' president, a combined team of 800+ employees is working together to tackle the workarounds and decision-making challenges that scientists are facing in today''s market. Today, we are assisting companies like BAS-F, Merck, and Novartis Pharma AG, and research universities like MIT and Oxford, providing solutions that can harmonize science and data.
Following the merger of Insightful Science and Dotmatics in March 2021, a global team of 800+ employees will assist its customers in more than 180 countries. Dotmatics has recently added senior executives including a CFO, CRO, and CMO, and will continue to build and acquire innovative scientific software solutions that are crucial in lab research. Dotmatics has received and continue to grow on its inorganic growth strategy through its 2021 strategy, which is expected to increase to more than $200 million in annual revenues
